INFLUENCE OF SPEED, TIME OF HOMOGENIZATION, TYPE OF SURFACE ACTIVE SUBSTANCE ON THE SIZE OF PENTOXYPHILLINE NANOPARTICLES BASED ON POLY-DL-LAKTIDE-CO-GLICOLIDE

Nanopharmacology is a set of methods and techniques used in the creation, study, production and use of nanostructures (size about 1–700 nm) with new chemical, physical, and biological properties. For a long time pharmacologists have been working on molecular, and sometimes even on a submolecular level for synthesizing new drugs and explaining their mechanism of action. Thanks to this, the interest of pharmacology in nanotechnology is connected with new ways of obtaining and using medicines. One way of obtaining new forms of drugs is the synthesis of nanoparticles, since they allow the active substance to overcome the protective barriers of the body such as, for example, the immune system. Due to the fact that the surface of nanoparticles (nanocapsules) is multilayered, their resistance to the action of the protective mechanisms of the body increases, which allows the drug to retain the activity of the pharmacological action, as well as its structure for a longer time. The possibility of penetration through biological barriers, tissue-specificity, rate of drug release depends largely on the size and surface properties of nanoparticles.

The aim of our study was to study the influence of such important factors as time, homogenization rate and the type of surface active substance, on the size of the obtained nanoparticles of pentoxifylline based on poly-DL-lactide-co-glycolide (PLGA).

Materials and methods. The research was carried out using the information retrieval database (PubMed), as well as the results of our own research.

Results and discussion. It has been found that the dispersion phase of the sample, in which polyvinyl alcohol was used as the surfactant, had the smallest size, particularly, the average hydrodynamic radius of the particles amounted to 175.4 nm. The influence of the speed and time of homogenization on the size of nano particles of pentoxifylline based on PLGA was experimentally proved. Also, microphotographs of nanoparticles of pentoxifylline based on poly-DL-lactide-coglycolide (PLGA) are presented.

Conclusion.Our studies prove the effect of the speed and time of homogenization, as well as the type of surfactant, on the size of nanoparticles of pentoxifylline based on poly-DL-lactide-co-glycolide. As a result of the studies, the procedure for obtaining nanoparticles of pentoxifylline was adjusted. 

1. Begdullaev A.K., Mansharipova A.T., Djusipov A.K., Abilayayli J.A. PROBLEMA NAPRAVLENNOGO TRANSPORTA LEKARSTVENNYH VESHCHESTV V KLINICHESKOJ PRAKTIKE [THE PROBLEM OF DIRECTIONAL TRANSPORT OF DRUGS IN CLINICAL PRACTICE]. Terapevticheskij vestnik [Therapeutic Bulletin]. 2008. No. 1. P. 32–36. (In Russ.)

2. Ivonin A.G., Pimenov E.V., Oborin V.A., Devrishov D.A., Kopilov S.N. NAPRAVLENNYJ TRANSPORT LEKARSTVENNYH PREPARATOV SOVREMENNOE SOSTOYANIE VOPROSA I PERSPEKTIVY [DIRECTIONAL TRANSPORT OF DRUGS: THE CURRENT STATE OF THE ISSUE AND PROSPECTS]. Izvestiya Komi nauchnogo centra UrO RAN [Proceedings of the Komi Scientific Center, Ural Branch of the Russian Academy of Sciences]. 2012. No. 1. P. 46–55. (In Russ.)

3. Chazov E.I., Smirnov V.N., Torchilin V.P. NAPRAVLENNYJ TRANSPORT LEKARSTV PROBLEMY I PERSPEKTIVY [DIRECTIONAL TRANSPORT OF DRUGS: PROBLEMS AND PROSPECTS]. Hurnal Vsesoyuznogo himicheskogo obshchestva im D I Mendeleeva [Journal of the All-Union Chemical Society. D.I. Mendeleev University]. 1987. Vol. 32. No. 5. P. 485–487. (In Russ.)

4. Shlyakhto E.V. INNOVACIONNYE NANOTEKHNOLOGII V MEDICINE I BIOLOGII [INNOVATIVE NANOTECHNOLOGIES IN MEDICINE AND BIOLOGY]. Инновации [Innovations]. 2008. No. 6. P. 54–59. (In Russ.)

5. Meider V.A. NANOTEKHNOLOGIYA KAK NOVAYA REALNOST [NANOTECHNOLOGY AS A NEW REALITY]. Zdravyj smysl [Common sense]. 2011. № 3. URL: http://razumru.ru/humanism/journal/60/authors.htm/ (date of the application: 22.02.2017). (In Russ.)

6. Ebbesen M., Jensen T.G. NANOMEDICINE: TECHNIQUES, POTENTIALS, AND ETHICAL IMPLICATIONS. J. Biomed. Biotechnol. 2006. N. 5. P. 515–516. DOI: 10.1155/JBB/2006/51516

7. Young M. B., MacConell L., Sarin V., Trautmann M., Herbert P. ENCAPSULATION OF EXENATIDE IN POLY-(D,L-LACTIDE-CO-GLYCOLIDE) MICROSPHERES PRODUCED AN INVESTIGATIONAL LONG-ACTING ONCE-WEEKLY FORMULATION FOR TYPE 2 DIABETES. Diabetes Technol Ther. 2011. No. 13. P. 1145–1154. DOI: 10.1089/dia.2011.0050

8. Minko N.I., Strokova V.V., Jernovskii I.V., Narcev V.M. Metody polucheniya i svojstva nanoobektov [Methods of obtaining and properties of nanoobjects]. Flinta: Nauka [Flinta: Science], 2009. 168 p. (In Russ.)

9. Tishkov T.M., Pogrebnyak A.V., Pogrebnyak L.V. SOVREMENNYE VSPOMOGATELNYE VESHCHESTVA [MODERN EXCIPIENTS]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2015. № 2(1). URL:https://science-education.ru/ru/article/view?id=24996/ (date of the application: 22.02.2017). DOI: 10.17513/spno.2015.2 (In Russ.)

10. Timchenko T.V., Shcherbakova L.I., Kompantsev V.A. POLI-D L-LAKTID-KO-GLIKOLID METODY POLUCHENIYA SVOJSTVA I ISPOLZOVANIE DLYA RAZRABOTKI LEKARSTVENNYH PREPARATOV SO SREDSTVAMI MIKRO- I NANODOSTAVKI [POLY-D, L-LACTIDE-CO-GLYCOLIDE: METHODS OF PREPARATION, PROPERTIES AND USE FOR THE DEVELOPMENT OF DRUGS WITH MICRO- AND NANOSCALE SUPPLIES]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2015. №4. URL: http://www.science-education.ru/ru/article/view?id=20840 (date of the application: 17.07.2016). (In Russ.)

11. Kuznetsova I.G., Severin S.E. ISPOLZOVANIE SOPOLIMERA MOLOCHNOJ I GLIKOLEVOJ KISLOT DLYA POLUCHENIYA NANORAZMERNYH LEKARSTVENNYH FORM [USE OF A COPOLYMER OF LACTIC AND GLYCOLIC ACIDS FOR THE PREPARATION OF NANOSIZED DOSAGE FORMS]. Razrabotka i registraciya lekarstvennyh sredstv [Development and registration of drugs]. 2013. №5. P. 30–38. (In Russ.)

12. Quinh Bui Thi Zuong., Blinskaya E.V., Alyautdin R.N., Ramenskaya G.V., Balabaniyan V.U. FARMAKOKINETICHESKOE IZUCHENIE NANOSOMALNOJ I SVOBODNOJ FORM SPARFLOKSACINA [PHARMACOKINETIC STUDY NANOSOMAL AND FREE FORMS OF SPARFLOXACIN]. Farmaciya [Pharmacy]. 2010. № 2. P. 42–44. (In Russ.)

13. Klimova O.V., Godovanniy A.V., Ryabceva M.C., Voroncov E.A., Severin E.S. IZUCHENIE NANOSOMALNOJ LEKARSTVENNOJ FORMY LOMEFLOKSACINA POLUCHENNOJ NA OSNOVE SOPOLIMEROV MOLOCHNOJ I GLIKOLEVOJ KISLOT NA NALICHIE SPECIFICHESKOJ AKTIVNOSTI I PROLONGIROVANNOGO EFFEKTA [THE STUDY NANOSOMAL DOSAGE FORMS OF LOMEFLOXACIN DERIVED FROM COPOLYMERS OF LACTIC AND GLYCOLIC ACIDS IN THE PRESENCE OF SPECIFIC ACTIVITY AND PROLONGED EFFECT]. Molekulyarnaya medicina [Molecular medicine]. 2010. No. 5 (In Russ.)

14. Dutta R.C. DRUG CARRIERS IN PHARMACEUTICAL DESIGN: PROMISES AND PROGRESS. Curr. Pharm. 2007. No. 7. P. 761–769.

15. Euliss L.E. IMPARTING SIZE, SHAPE, AND COMPOSITION CONTROL OF MATERIALS FOR NANOMEDICINE. Chem. Soc. Rev. 2006. N 35 (11). P. 1095-104. DOI: 10.1039/b600913c

16. Medvedeva N.V., Ipatova O.M., Ivanov luD, Drozhzhin A.I., Archakov A.I. NANOBIOTECHNOLOGY AND NANOMEDICINE. Biomed Khim. 2006. No. 52 (6). P. 529–546.

17. Cai Q., Wang L. , Deng G., Liu J., Chen Q., Chen Z. SYSTEMIC DELIVERY TO CENTRAL NERVOUS SYSTEM BY ENGINEERED PLGA NANOPARTICLES. Am J Transl Res. 2016. No. 8(2). P. 749–764.